APVO
$45.99
Aptevo Therapeutics
($1.77)
(3.71%)
APVO
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($1.79)
Revenue:  $1.67 Mil
Tuesday
Feb 9
After the close
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when APVO reports earnings?
Beat
Meet
Miss

Where is APVO's stock price going from here?
Up
Flat
Down
Stock chart of APVO
Analysts
Summary of analysts' recommendations for APVO
Score
Grade
Pivots
Resistance
$49.87
$48.92
$47.46

$46.51

Support
$45.05
$44.10
$42.64
Tweet
Growth
Description
Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics Inc. is based in Seattle, Washington.